Labcorp Holdings (N6B) Stock Forecast & Price Target

9 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

N6B Analyst Ratings

Strong Buy

9 Buy

3 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Labcorp

Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

N6B Stock 12 Month Forecast

Average Price Target

€292.76

▲(16.18% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Labcorp Holdings in the last 3 months. The average price target is €292.76 with a high forecast of €312.43 and a low forecast of €264.83. The average price target represents a 16.18% change from the last price of €252.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"209":"€209","235":"€235","261":"€261","287":"€287","313":"€313"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":312.43103473,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€312.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":292.7614908663636,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€292.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":264.83073858,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€264.83</span>\n  </div></div>","useHTML":true}}],"tickPositions":[209,235,261,287,313],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,272,275.1100795946154,278.2201591892308,281.33023878384614,284.44031837846154,287.55039797307694,290.66047756769234,293.7705571623077,296.8806367569231,299.9907163515385,303.1007959461539,306.2108755407692,309.3209551353846,{"y":312.43103473,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,272,273.59703775895105,275.1940755179021,276.79111327685314,278.3881510358042,279.98518879475523,281.5822265537063,283.1792643126573,284.77630207160837,286.3733398305594,287.97037758951046,289.5674153484615,291.16445310741256,{"y":292.7614908663636,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,272,271.4485183523077,270.8970367046154,270.3455550569231,269.79407340923075,269.24259176153845,268.69111011384615,268.13962846615385,267.58814681846155,267.03666517076925,266.4851835230769,265.9337018753846,265.3822202276923,{"y":264.83073858,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":221.616,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.111,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.047,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.778,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.863,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.799,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.315,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.383,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€312.43

Average Price Target€292.76

Lowest Price Target€264.83

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ann Hynes

Mizuho Securities

€276.95→€307.24

Buy

21.92%

Upside

Reiterated

08/10/26

Labcorp price target raised to $355 from $320 at MizuhoLabcorp price target raised to $355 from $320 at Mizuho

David Westenberg

Piper Sandler

€259.64→€267.43

Hold

6.12%

Upside

Reiterated

08/04/26

Piper Sandler Remains a Hold on Labcorp Holdings (LH)

Lisa Gill

J.P. Morgan

€285.6→€311.57

Buy

23.64%

Upside

Assigned

08/03/26

Labcorp price target raised to $360 from $330 at JPMorganLabcorp price target raised to $360 from $330 at JPMorgan

Erin Wright

Morgan Stanley

€266.56→€292.53

Buy

16.08%

Upside

Reiterated

07/31/26

Morgan Stanley Sticks to Their Buy Rating for Labcorp Holdings (LH)

David S Macdonald

Truist Financial

€276.95→€302.91

Buy

20.20%

Upside

Reiterated

07/31/26

Truist Financial Sticks to Their Buy Rating for Labcorp Holdings (LH)

Eric Coldwell

Robert W. Baird

€292.53→€304.64

Buy

20.89%

Upside

Reiterated

07/31/26

Labcorp price target raised to $352 from $338 at BairdLabcorp price target raised to $352 from $338 at Baird

Pito Chickering

Deutsche Bank

€238.87→€264.83

Hold

5.09%

Upside

Assigned

07/31/26

Labcorp price target raised to $306 from $276 at Deutsche BankLabcorp price target raised to $306 from $276 at Deutsche Bank

Luke Sergott

Barclays

€250.98→€276.95

Hold

9.90%

Upside

Reiterated

07/31/26

Labcorp price target raised to $320 from $290 at BarclaysLabcorp price target raised to $320 from $290 at Barclays

Kevin Caliendo

UBS

€276.95→€312.43

Buy

23.98%

Upside

Reiterated

07/31/26

UBS Remains a Buy on Labcorp Holdings (LH)

Michael Ryskin

Bank of America Securities

€276.95→€311.57

Buy

23.64%

Upside

Reiterated

07/30/26

Labcorp: Guidance Raised, Biopharma Momentum Strengthens, and Price Target Increased to $360 on Higher FY27 EBITDA Multiple

Jared Haase

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (NYSE: LH) and Cytokinetics (NASDAQ: CYTK)

David Toung

Argus Research

€268.29

Buy

6.47%

Upside

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (NYSE: LH), Moderna (NASDAQ: MRNA) and Celcuity (NASDAQ: CELC)

Elizabeth Anderson CFA

Evercore ISI

€259.64

Buy

3.03%

Upside

Reiterated

05/01/26

Evercore ISI Keeps Their Buy Rating on Labcorp Holdings (LH)

Patrick B Donnelly

Citi

€281.27

Buy

11.62%

Upside

Reiterated

01/02/26

Analysts' Top Healthcare Picks: Doximity (DOCS), Labcorp Holdings (LH)

Michael Cherny

Leerink Partners

€279.54→€295.99

Buy

17.46%

Upside

Reiterated

10/08/25

Leerink Partners Reaffirms Their Buy Rating on Labcorp Holdings (LH)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ann Hynes

Mizuho Securities

€276.95→€307.24

Buy

21.92%

Upside

Reiterated

08/10/26

Labcorp price target raised to $355 from $320 at MizuhoLabcorp price target raised to $355 from $320 at Mizuho

David Westenberg

Piper Sandler

€259.64→€267.43

Hold

6.12%

Upside

Reiterated

08/04/26

Piper Sandler Remains a Hold on Labcorp Holdings (LH)

Lisa Gill

J.P. Morgan

€285.6→€311.57

Buy

23.64%

Upside

Assigned

08/03/26

Labcorp price target raised to $360 from $330 at JPMorganLabcorp price target raised to $360 from $330 at JPMorgan

Erin Wright

Morgan Stanley

€266.56→€292.53

Buy

16.08%

Upside

Reiterated

07/31/26

Morgan Stanley Sticks to Their Buy Rating for Labcorp Holdings (LH)

David S Macdonald

Truist Financial

€276.95→€302.91

Buy

20.20%

Upside

Reiterated

07/31/26

Truist Financial Sticks to Their Buy Rating for Labcorp Holdings (LH)

Eric Coldwell

Robert W. Baird

€292.53→€304.64

Buy

20.89%

Upside

Reiterated

07/31/26

Labcorp price target raised to $352 from $338 at BairdLabcorp price target raised to $352 from $338 at Baird

Pito Chickering

Deutsche Bank

€238.87→€264.83

Hold

5.09%

Upside

Assigned

07/31/26

Labcorp price target raised to $306 from $276 at Deutsche BankLabcorp price target raised to $306 from $276 at Deutsche Bank

Luke Sergott

Barclays

€250.98→€276.95

Hold

9.90%

Upside

Reiterated

07/31/26

Labcorp price target raised to $320 from $290 at BarclaysLabcorp price target raised to $320 from $290 at Barclays

Kevin Caliendo

UBS

€276.95→€312.43

Buy

23.98%

Upside

Reiterated

07/31/26

UBS Remains a Buy on Labcorp Holdings (LH)

Michael Ryskin

Bank of America Securities

€276.95→€311.57

Buy

23.64%

Upside

Reiterated

07/30/26

Labcorp: Guidance Raised, Biopharma Momentum Strengthens, and Price Target Increased to $360 on Higher FY27 EBITDA Multiple

Jared Haase

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (NYSE: LH) and Cytokinetics (NASDAQ: CYTK)

David Toung

Argus Research

€268.29

Buy

6.47%

Upside

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (NYSE: LH), Moderna (NASDAQ: MRNA) and Celcuity (NASDAQ: CELC)

Elizabeth Anderson CFA

Evercore ISI

€259.64

Buy

3.03%

Upside

Reiterated

05/01/26

Evercore ISI Keeps Their Buy Rating on Labcorp Holdings (LH)

Patrick B Donnelly

Citi

€281.27

Buy

11.62%

Upside

Reiterated

01/02/26

Analysts' Top Healthcare Picks: Doximity (DOCS), Labcorp Holdings (LH)

Michael Cherny

Leerink Partners

€279.54→€295.99

Buy

17.46%

Upside

Reiterated

10/08/25

Leerink Partners Reaffirms Their Buy Rating on Labcorp Holdings (LH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Labcorp Holdings

3 Months

Erin WrightMorgan Stanley

Success Rate

16/22 ratings generated profit

Average Return

+4.93%

Copying Erin Wright's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +4.93% per trade.

1 Year

Lisa GillJ.P. Morgan

Success Rate

13/13 ratings generated profit

Average Return

+18.22%

Copying Lisa Gill's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.22% per trade.

2 Years

Erin WrightMorgan Stanley

Success Rate

22/22 ratings generated profit

Average Return

+30.01%

Copying Erin Wright's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +30.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

N6B Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, N6B has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. N6B average Analyst price target in the past 3 months is 292.76.

Each month's total comprises the sum of three months' worth of ratings.

N6B Financial Forecast

N6B Earnings Forecast

Next quarter’s earnings estimate for N6B is €4.04 with a range of €3.90 to €4.11. The previous quarter’s EPS was €4.33. N6B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.49% of the time in the same period. In the last calendar year N6B has Performed in-line its overall industry.

N6B Sales Forecast

Next quarter’s sales forecast for N6B is €3.26B with a range of €3.24B to €3.28B. The previous quarter’s sales results were €3.24B. N6B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.42% of the time in the same period. In the last calendar year N6B has Performed in-line its overall industry.

N6B Stock Forecast FAQ

What is DE:N6B’s average 12-month price target, according to analysts?

Based on analyst ratings, Labcorp Holdings’s 12-month average price target is 292.76.

What is DE:N6B’s upside potential, based on the analysts’ average price target?

Labcorp Holdings has 16.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Labcorp Holdings a Buy, Sell or Hold?

Labcorp Holdings has a consensus rating of Strong Buy, which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.

What is Labcorp Holdings’s share price target?

The average share price target for Labcorp Holdings is 292.76. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €312.43 ,and the lowest forecast is €264.83. The average share price target represents 16.18% Increase from the current price of €252.

What do analysts say about Labcorp Holdings?

Labcorp Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Labcorp Holdings?

To buy shares of DE:N6B, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Labcorp Holdings (N6B) Stock Forecast & Price Target

N6B Analyst Ratings

N6B Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Labcorp Holdings

N6B Analyst Recommendation Trends

N6B Financial Forecast

N6B Earnings Forecast

N6B Sales Forecast

N6B Stock Forecast FAQ

Detailed List of Analyst Forecasts